The TRACK-ER study shows ctDNA positivity isn't just a future risk predictor. Nearly half (44%) of patients with a newly positive ctDNA test were found to have metastatic disease on imaging. This suggests ctDNA often detects existing, micrometastatic disease that standard scans miss, challenging the distinction between early-stage surveillance and managing overt metastatic cancer.

The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

In early-stage non-small cell lung cancer, the presence of circulating tumor DNA before surgery is not a statistically significant predictor of survival. However, detecting ctDNA after curative-intent surgery is a strong negative prognostic indicator, highlighting the critical value of post-operative testing.

Kidney cancer has lagged other tumor types in adopting circulating tumor DNA (ctDNA) analysis because it sheds very little DNA into the blood. Only recently have diagnostic assays become sensitive enough to reliably detect it, finally unlocking its potential as a clinical biomarker for guiding adjuvant therapy.

In muscle-invasive bladder cancer, patients whose cell-free DNA remains positive after surgery almost uniformly experience disease relapse. This makes ctDNA a powerful prognostic tool, akin to PSA in prostate cancer, for identifying patients at the highest risk.

Many deaths from colon cancer occur in patients with Stage II disease not offered adjuvant therapy due to a lack of traditional risk factors. Post-surgical ctDNA testing can identify a ~10% subset with minimal residual disease who are at high risk of recurrence and would benefit from chemotherapy.

Experts warn against over-interpreting a single negative ctDNA test after surgery, clarifying that these patients still face a significant 25-30% risk of recurrence. The biomarker's true prognostic power comes from serial testing that shows a patient remains persistently negative over time.

Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.